scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Thunalbene, a stilbene derivative from the orchid Thunia alba

20 Dec 1998-Phytochemistry (Pergamon)-Vol. 49, Iss: 8, pp 2375-2378
TL;DR: Thunalbene, a new stilbene derivative, was isolated from the orchid Thunia alba which also afforded six known stilbenoids: batatasin-III, lusianthridin, 3,7-dihydroxy-2,4-dimethoxyphenanthrene, 3.5methoxystilbenoid and flavanthrin this paper.
About: This article is published in Phytochemistry.The article was published on 1998-12-20. It has received 50 citations till now.
Citations
More filters
Journal ArticleDOI
TL;DR: Chemical investigation of Dendrobium plicatile Lindl resulted in the isolation and identification of one new bibenzyl, 2-chloro-3, 4’-dihydroxy-3’,5-dimethoxybibensyl (1), as well as 15 known stilbenoids.

11 citations


Cites background from "Thunalbene, a stilbene derivative f..."

  • ...…(Majumder and Banerjee 1990) and calanhydroquinone C(13) (Lee et al. 2009), three known phenanthrene, 3,7-dihydroxy-2,4-dimethoxy-phenanthrene(14) (Majumder et al. 1998), nudol(15) (Bhandari et al. 1985) and denthyrsinin(16) (Zhang et al. 2005), were identified through comparison of their…...

    [...]

  • ...2009), three known phenanthrene, 3,7-dihydroxy-2,4-dimethoxy-phenanthrene(14) (Majumder et al. 1998), nudol(15) (Bhandari et al....

    [...]

Journal ArticleDOI
TL;DR: A new bibenzyl derivative, named 2-(4′-hydroxybenzyl)-3-(3′hydroxyphenethyl)-5-methoxy-cyclohexa-2,5-diene-1,4-dione, and two known stilbenoids (2, 3 ) were isolated from the tubers of Pleione bulbocodioides (Franch.) Rolfe as mentioned in this paper.

10 citations

Journal ArticleDOI
TL;DR: Wang et al. as discussed by the authors extracted 15 compounds from the active extract of Pholidota cantonensis and evaluated their bio-activities, including one new compound, including 2,2′-diphenyl-1-picrylhydrazyl (DPPH) and 3,ethylbenzothiazoline-6-sulfonic acid (ABTS).
Abstract: Alzheimer’s disease (AD) has the third highest health expenditures after heart disease and cancer. It has emerged as a serious global health issue. The discovery of new drugs to prevent and treat AD is of utmost importance. Pholidota cantonensis is an edible medicinal plant consumed in China. It is widely used in traditional Chinese medicine to treat various diseases. P. cantonensis has been reported to have antioxidant, anti-inflammatory, antitumor and antibacterial activities. Among these properties, its potent antioxidant activity has attracted our attention, since oxidative stress is one of the important pathological mechanisms involved in AD. This study aimed to isolate the compounds from the active extract and evaluate their bioactivities. Fifteen compounds, including one new compound, were obtained. The isolates were tested for 2,2′-diphenyl-1-picrylhydrazyl (DPPH)/2,2′-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical scavenging activities, anti-acetylcholinesterase (anti-AChE) activities and inhibitory effects on nitrogen monoxide (NO) release in the BV-2 cells. Compounds 1, 2, 4, 6, 8, and 13–15 exhibited two kinds of AD-associated bioactivities. More importantly, compound 13 showed more potent NO inhibitory activity (IC50 = 0.72 ± 0.08 μM) than the positive control quercetin (IC50 = 12.94 ± 0.08 μM). Compound 13 also had a higher inhibitory rate (99.59 ± 0.43%) on AChE than that of the positive control galantamine (78.32 ± 1.16%) at the concentrate of 50 μg/mL. Our studies provide new insights into this plant in terms of its potential in the development of new multi-target anti-Alzheimer’s disease (anti-AD) drugs.

8 citations

Journal ArticleDOI
TL;DR: It can be concluded that numerous molecules have displayed significant results and their promising potential, clearly placing them ahead as potential future drug candidates.
Abstract: GABA (γ-amino butyric acid) is an important inhibitory neurotransmitter in the central nervous system. Attenuation of GABAergic neurotransmission plays an important role in the etiology of several neurological disorders including epilepsy, Alzheimer's disease, Huntington's chorea, migraine, Parkinson's disease, neuropathic pain, and depression. Increase in the GABAergic activity may be achieved through direct agonism at the GABAA receptors, inhibition of enzymatic breakdown of GABA, or by inhibition of the GABA transport proteins (GATs). These functionalities make GABA receptor modulators and GATs attractive drug targets in brain disorders associated with decreased GABA activity. There have been several reports of development of GABA modulators (GABA receptors, GABA transporters, and GABAergic enzyme inhibitors) in the past decade. Therefore, the focus of the present review is to provide an overview on various design strategies and synthetic approaches toward developing GABA modulators. Furthermore, mechanistic insights, structure-activity relationships, and molecular modeling inputs for the biologically active derivatives have also been discussed. Summary of the advances made over the past few years in the clinical translation and development of GABA receptor modulators is also provided. This compilation will be of great interest to the researchers working in the field of neuroscience. From the light of detailed literature, it can be concluded that numerous molecules have displayed significant results and their promising potential, clearly placing them ahead as potential future drug candidates.

7 citations

References
More filters
Book
01 Jan 1989

1,786 citations

Journal ArticleDOI
TL;DR: The structural simplicity and ready synthesis of combretastatin A-1 and combretastsatin B-1 suggest that these new biosynthetic products will become useful in a variety of biological endeavors.
Abstract: The principal antineoplastic constituent of the South African tree Combretum caffrum has been isolated and designated combretastatin A-1. The structure of this new cis-stilbene was unequivocally established by X-ray crystal structure determination and total synthesis. A Wittig reaction sequence in THF comprised the synthetic key step (92.5% yield) and provided a very favorable 9:1 ratio of the cis:trans [1c:2c, geometrical isomers]. Selective hydrogenation of combretastatin A-1 afforded combretastatin B-1, a companion cell growth inhibitory constituent of C. caffrum. Combretastatin A-1 provided 26-29% life extension at 2.75-11 mg/kg dose levels with ED50 0.99 microgram/ml against the murine P-388 lymphocytic leukemia in vivo and in vitro systems. Both combretastatin A-1 and combretastatin B-1 are potent inhibitors of microtubule assembly in vitro and among the most potent inhibitors of the binding of colchicine to tubulin yet described. The structural simplicity and ready synthesis of combretastatin A-1 and combretastatin B-1 suggest that these new biosynthetic products will become useful in a variety of biological endeavors.

291 citations

Journal ArticleDOI
TL;DR: Three new substituted bibenzyls (1,2-diarylethanes) aloifol I and aloIFol II and a new substituted 9,10-dihydrophenanthrene, 6-O-methylcoelonin in addition to batatasin III, coel onin and gigantol have been isolated and characterized.

70 citations

Journal ArticleDOI
TL;DR: Lusianthrin and lusian-thridin, two new stilbenoids, were isolated from the orchid Lusia indivisa.

66 citations

Journal ArticleDOI
TL;DR: In this paper, eleven major non-polar constituents of the dried bark of Virola elongata were isolated and the structures of virolongin, dihydrosesartemin and β-dihydroyangambin were determined.

65 citations